CA
TXMD icon

Calton & Associates’s TherapeuticsMD TXMD Stock Holding History

Calton & Associates’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200
Closed -$3K – 350
2022
Q1 		$3K Buy
+200
New +$3.15K ﹤0.01% 349
2021
Q4 		– Sell
-240
Closed -$8K – 408
2021
Q3 		$8K Hold
240
– – ﹤0.01% 395
2021
Q2 		$15K Hold
240
– – ﹤0.01% 406
2021
Q1 		$16K Sell
240
-40
-14% -$3.13K ﹤0.01% 397
2020
Q4 		$17K Sell
280
-100
-26% -$6.83K ﹤0.01% 382
2020
Q3 		$30K Buy
380
+40
+12% +$3.19K 0.01% 346
2020
Q2 		$21K Sell
340
-10
-3% -$582 ﹤0.01% 331
2020
Q1 		$19K Buy
+350
New +$34.7K ﹤0.01% 303

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Calton & Associates's TXMD Position: Q2 2022 in Review

Calton & Associates sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 200 shares — an estimated $3K sold.

Calton & Associates first reported a position in TXMD in Q1 2020 and held it in 8 quarters. The position peaked at $30K in Q3 2020. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Calton & Associates reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Calton & Associates sold 200 TherapeuticsMD shares in Q2 2022, an estimated $3K.
  • Calton & Associates first reported a position in TherapeuticsMD in Q1 2020 and held it in 8 quarters.
  • Calton & Associates's TherapeuticsMD position peaked at $30K in Q3 2020.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Calton & Associates's 13F filing for Q2 2022, filed 12 Jul 2022.